TY - JOUR
T1 - Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization
AU - Khachatryan, Tigran
AU - Hauschild, Christopher
AU - Hoff, Jason
AU - Contractor, Tahmeed
AU - Khachatryan, Arthur
AU - Tran, Huyentran
AU - Matsuo, Bert
AU - Jacobson, Alan
AU - Hilliard, Anthony
N1 - Publisher Copyright:
© 2019, Springer Nature Switzerland AG.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Direct oral anticoagulants (DOACs) have been developed as a viable and in some cases superior alternative to warfarin. These agents have overcome some of the limitations of warfarin, which has a narrow therapeutic window and many food and drug interactions. DOACs have been demonstrated to have a more predictable and reliable pharmacology and, unlike warfarin, do not require frequent monitoring of anticoagulant effect. For these reasons, the use of DOACs is increasing. Despite the many positive attributes of these agents, limitations and contraindications do exist. An understanding of the pharmacology, indications, and contraindications is therefore crucial for effective patient management. We review the available agents to aid in effective drug utilization.
AB - Direct oral anticoagulants (DOACs) have been developed as a viable and in some cases superior alternative to warfarin. These agents have overcome some of the limitations of warfarin, which has a narrow therapeutic window and many food and drug interactions. DOACs have been demonstrated to have a more predictable and reliable pharmacology and, unlike warfarin, do not require frequent monitoring of anticoagulant effect. For these reasons, the use of DOACs is increasing. Despite the many positive attributes of these agents, limitations and contraindications do exist. An understanding of the pharmacology, indications, and contraindications is therefore crucial for effective patient management. We review the available agents to aid in effective drug utilization.
KW - Dose-Response Relationship, Drug
KW - Antithrombins/adverse effects
KW - Administration, Oral
KW - Humans
KW - Stroke/prevention & control
KW - Anticoagulants/adverse effects
KW - Drug Monitoring
KW - Drug Utilization
KW - Factor Xa Inhibitors/adverse effects
UR - http://www.scopus.com/inward/record.url?scp=85064338150&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064338150&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/5c8da567-f653-3de7-90bf-e180a36b1f58/
U2 - 10.1007/s40256-019-00344-6
DO - 10.1007/s40256-019-00344-6
M3 - Article
C2 - 30941708
SN - 1175-3277
VL - 19
SP - 525
EP - 539
JO - American Journal of Cardiovascular Drugs
JF - American Journal of Cardiovascular Drugs
IS - 6
ER -